Zenas BioPharma Accounts Payable

Zenas BioPharma (ZBIO) currently reports a accounts payable of $8.9M as of March 2026. That compares with $20M in the prior-year period — down 55.3% year over year. Use the charts on this page to explore Zenas BioPharma's accounts payable history and peer comparisons.

Zenas BioPharma's accounts payable decreased from $20M to $8.9M — a 55.3% year-over-year decrease (period ending March 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Zenas BioPharma reported $8.9M in accounts payable as of March 2026. That compares with $20M in the prior-year period — down 55.3% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current accounts payable of $8.9M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Zenas BioPharma, and consider following ZBIO for alerts when major investors trade the stock.

Zenas BioPharma is classified in the Healthcare sector. On accounts payable, it currently shows $8.9M. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing ZBIO with unrelated industries.